Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms (Q38017138)

27 August 2017

Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms (English)

1 reference

27 August 2017

1 reference

Simone Ferrero

1

1 reference

27 August 2017

Daniela Drandi

2

1 reference

27 August 2017

Barbara Mantoan

3

1 reference

27 August 2017

Paola Ghione

4

1 reference

27 August 2017

Paola Omedè

5

1 reference

27 August 2017

Marco Ladetto

6

1 reference

27 August 2017

2 April 2011

1 reference

27 August 2017

Hematological Oncology

1 reference

27 August 2017

29

1 reference

27 August 2017

4

1 reference

27 August 2017

167-176

1 reference

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

27 August 2017

1 reference

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

21 January 2018

1 reference

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

21 January 2018

1 reference

''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases

21 January 2018

1 reference

BCL2 translocation frequency rises with age in humans

21 January 2018

1 reference

Characterization of the t(14;18) BCL2-IGH translocation in farmers occupationally exposed to pesticides.

21 January 2018

1 reference

PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy.

21 January 2018

1 reference

Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone.

21 January 2018

1 reference

Somatic generation of antibody diversity

21 January 2018

1 reference

Cellular origin of human B-cell lymphomas.

21 January 2018

1 reference

Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma

21 January 2018

1 reference

Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications.

21 January 2018

1 reference

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

21 January 2018

1 reference

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

21 January 2018

1 reference

Clonal evolution of a follicular lymphoma: evidence for antigen selection

21 January 2018

1 reference

Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase

21 January 2018

1 reference

A novel method for real time quantitative RT-PCR.

21 January 2018

1 reference

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

21 January 2018

1 reference

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma

21 January 2018

1 reference

Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission

21 January 2018

1 reference

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

21 January 2018

1 reference

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

21 January 2018

1 reference

Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma

21 January 2018

1 reference

One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?

21 January 2018

1 reference

BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study

21 January 2018

1 reference

Current treatment standards and emerging strategies in mantle cell lymphoma

21 January 2018

1 reference

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

21 January 2018

1 reference

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

21 January 2018

1 reference

Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

21 January 2018

1 reference

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

21 January 2018

1 reference

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

21 January 2018

1 reference

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

21 January 2018

1 reference

Multiple myeloma: chemotherapy or transplantation in the era of new drugs.

21 January 2018

1 reference

A comparison of allografting with autografting for newly diagnosed myeloma

21 January 2018

1 reference

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

21 January 2018

1 reference

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

21 January 2018

1 reference

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

21 January 2018

1 reference

Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation.

21 January 2018

1 reference

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma

21 January 2018

1 reference

Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.

21 January 2018

1 reference

A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma

21 January 2018

1 reference

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

21 January 2018

1 reference

Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice

21 January 2018

1 reference

Optimal use of prognostic factors in non-Hodgkin lymphoma

21 January 2018

1 reference

The role of FDG-PET scans in patients with lymphoma

21 January 2018

1 reference

Prognostic factors in follicular lymphoma.

21 January 2018

1 reference

Attainment of molecular remission: a worthwhile goal?

21 January 2018

1 reference

7 January 2021

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall s

1 reference

7 January 2021

Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas

1 reference

7 January 2021

Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma

1 reference

7 January 2021

A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

1 reference

7 January 2021

Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms

1 reference

7 January 2021

Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma

1 reference

7 January 2021

Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma

1 reference

7 January 2021

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

7 January 2021

Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.

1 reference

7 January 2021

Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes

1 reference

7 January 2021

High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up

1 reference

7 January 2021

Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma

1 reference

7 January 2021

Mantle-cell lymphoma: a population-based clinical study.

1 reference

7 January 2021

Refining "total therapy" for myeloma

1 reference

7 January 2021

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells

1 reference

7 January 2021

Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation

1 reference

7 January 2021

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma

1 reference

7 January 2021

Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.989

1 reference

27 August 2017

1 reference